PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence

BACKGROUND: Identification of novel molecular target(s) is important for designing newer mechanistically driven approaches for the treatment of prostate cancer (PCa), which is one of the main causes of morbidity and mortality in men. In this study, we determined the role of polo‐like kinase 4 (PLK4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Chandra K., Denu, Ryan A., Nihal, Minakshi, Shabbir, Maria, Garvey, Debra R., Huang, Wei, Iczkowski, Kenneth A., Ahmad, Nihal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090996/
https://www.ncbi.nlm.nih.gov/pubmed/35333404
http://dx.doi.org/10.1002/pros.24342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090996/
https://www.ncbi.nlm.nih.gov/pubmed/35333404
http://dx.doi.org/10.1002/pros.24342

Ejemplares similares